Fatigue and Patient Reported Outcomes (PROs) in Primary Sclerosing Cholangitis

2024-9-1

Submit your abstract for the EASL SLD Summit by 29 October

2024-9-1

The A-TANGO consortium performs Phase II clinical studies of an innovative therapeutic strategy, called "G-TAK", to fight end-stage cirrhosis and ACLF. Discover the project!

2024-9-1

Submit your abstract for the EASL Congress 2025 by 3 December

2024-9-1

Reply to: Hepatitis B Virus spliced 1 RNA, a key factor for viral expression

2024-9-1

Application of digital pathology in liver transplantation

2024-9-1

An overweight female with a history of allergies and drug-induced liver injury

2024-9-1

Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

2024-9-1

Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression

2024-9-1

Assessment of liver graft quality during hypothermic oxygenated perfusion: the first international validation study

2024-9-1

Reply: Implications of Mycophenolate Mofetil in a reproductive age patient cohort: Maternal Fetal Medicine point of view.

2024-9-1

Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma

2024-9-1

Contents

2024-9-1

Editorial Board

2024-9-1

Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study

2024-9-1

From the Editor’s Desk...

2024-9-1

Submit your abstract for the EASL Liver Cancer Summit by 12 November

2024-8-23

JHEP at a glance (September 2024)

2024-8-23

Colonel Stephen A. Harrison, M.D. – The passing of a Titan

2024-8-7

SPONTANEOUS CANDIDEMIA, A REAL INFECTION IN ADVANCED CIRRHOSIS

2024-8-1

In Memoriam: Rita Golfieri (1955-2024)

2024-8-1

A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B

2024-8-1

Association of PNPLA3 risk variant with steatotic liver disease among lean people with HIV mono-infection

2024-8-1

Frailty and risk of metabolic dysfunction–associated steatotic liver disease and other chronic liver diseases

2024-8-1

Reply to “MetALD accounts for a large part of what we call MASLD!”

2024-8-1

Integrating Strategic, Equity, and Socioeconomic Perspectives: A Holistic Approach to Advancing Hepatitis B Management and Outcomes

2024-8-1

Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis

2024-8-1

Contents

2024-8-1

Editorial Board

2024-8-1

Save the date for the EASL Liver Cancer Summit, 20-22 February 2025, Paris (France)

2024-8-1

Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding: a prospective cohort study

2024-8-1

Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study

2024-8-1

Targeting the liver clock improves fibrosis by restoring TGF-β signaling

2024-8-1

Variation in intention-to-treat survival by MELD subtypes: all models created for end-stage liver disease are not equal

2024-8-1

In Memoriam: Professor Paul McMaster (1943 to 2024)

2024-8-1

Reply to: Does encephalopathy with early onset after TIPS impact on mortality?

2024-8-1

Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids

2024-8-1

Leveraging normothermic liver machine perfusion as a platform for oncologic assessment in cirrhotic livers

2024-8-1

Reply to “What references and what gold standard should be used to assess myosteatosis in chronic liver disease ?”

2024-8-1

Optimising the treatment of HDV infection: efficacy of Bulevirtide, HBV-HDV interactions and the importance of statistical methods

2024-8-1

Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity

2024-8-1

Identification and functional validation of miR-190b-5p and miR-296-3p as novel therapeutic attenuators of liver fibrosis

2024-8-1

Association of Food Insecurity with the Prevalence and Liver-related Mortality of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

2024-8-1

JHEP at a glance (August 2024)

2024-8-1

See you next year in Amsterdam for the EASL Congress 2025!

2024-8-1

Save the date for the EASL SLD Summit 2025, 23-25 January 2025, Estoril (Portugal)

2024-8-1

Hs-CRP and HOMA-IR: include them in the MASLD definition, or treat them as mediators between MASLD and atherosclerotic cardiovascular disease?

2024-8-1

Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.

2024-8-1

A Turning point in Hepatology? EASL Reflects on the First Approved Drug for MASH

2024-8-1

FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma

2024-8-1